Economics Faculty Database
Economics
Arts & Sciences
Duke University
 HOME > Arts & Sciences > Economics > Faculty    Search Help Login pdf version printable version 

Publications of David B. Ridley    :chronological  alphabetical  combined  bibtex listing:

search faculty.fuqua.duke.edu.

Journal Articles

  1. Ridley, DB; Lasanta, AM; Storer Jones, F; Ridley, SK, European priority review vouchers for neglected disease product development., BMJ global health, vol. 9 no. 1 (January, 2024), pp. e013686, BMJ [doi]  [abs]
  2. Liebman, E; Lawler, EC; Dunn, A; Ridley, DB, Consequences of a shortage and rationing: Evidence from a pediatric vaccine., Journal of health economics, vol. 92 (December, 2023), pp. 102819, Elsevier BV [doi]  [abs]
  3. Cuddy, E; Lu, YP; Ridley, DB, FDA Global Drug Inspections: Surveillance Of Manufacturing Establishments Remains Well Below Pre-COVID-19 Levels., Health affairs (Project Hope), vol. 42 no. 12 (December, 2023), pp. 1758-1766 [doi]  [abs]
  4. Ridley, DB; Ganapathy, P; Kettler, HE, ​US Tropical Disease Priority Review Vouchers: Lessons In Promoting Drug Development And Access., Health affairs (Project Hope), vol. 40 no. 8 (August, 2021), pp. 1243-1251 [doi]  [abs]
  5. Ridley, DB; Lee, CY, Does medicare reimbursement drive up drug launch prices?, Review of Economics and Statistics, vol. 102 no. 5 (December, 2020), pp. 980-993 [doi]  [abs]
  6. Kyle, MK; Ridley, DB; Zhang, S, Strategic interaction among governments in the provision of a global public good, Journal of Public Economics, vol. 156 (December, 2017), pp. 185-199, Elsevier BV [doi]  [abs]
  7. Ridley, DB; Moe, JL; Hamon, N, A Voucher System To Speed Review Could Promote A New Generation Of Insecticides To Fight Vector-Borne Diseases., Health affairs (Project Hope), vol. 36 no. 8 (August, 2017), pp. 1461-1468 [doi]  [abs]
  8. Yurukoglu, A; Liebman, E; Ridley, DB, The role of government reimbursement in drug shortages, American Economic Journal: Economic Policy, vol. 9 no. 2 (May, 2017), pp. 348-382, American Economic Association [doi]  [abs]
  9. Ridley, DB; Zhang, S, Regulation of price increases, International Journal of Industrial Organization, vol. 50 (January, 2017), pp. 186-213, Elsevier BV [doi]  [abs]
  10. Ridley, DB, Priorities for the Priority Review Voucher., The American journal of tropical medicine and hygiene, vol. 96 no. 1 (January, 2017), pp. 14-15 [doi]  [abs]
  11. Basu, A; Axelsen, K; Grabowski, DC; Meltzer, DO; Polsky, D; Ridley, DB; Wiederkehr, D; Philipson, TJ, Real-World Data: Policy Issues Regarding their Access and Use., Medical care, vol. 54 no. 12 (December, 2016), pp. 1038-1044 [doi]  [abs]
  12. Basu, A; Axelsen, K; Grabowski, DC; Meltzer, DO; Polsky, D; Ridley, DB; Wiederkehr, D; Philipson, TJ, Real-World Data: Responses to Zito and Doshi., Medical care, vol. 54 no. 12 (December, 2016), pp. 1048-1049 [doi]
  13. Ridley, DB; Zhang, S, Regulation of Price Increases (August, 2016)
  14. Ridley, DB; Régnier, SA, The Commercial Market For Priority Review Vouchers., Health affairs (Project Hope), vol. 35 no. 5 (May, 2016), pp. 776-783 [doi]  [abs]
  15. Ridley, DB; Dent, J; Egerton-Warburton, C, Efficacy of the Priority Review Voucher Program., JAMA, vol. 315 no. 15 (April, 2016), pp. 1659-1660, ISSN 0098-7484 [doi]
  16. Ridley, DB; Bei, X; Liebman, EB, No Shot: US Vaccine Prices And Shortages., Health affairs (Project Hope), vol. 35 no. 2 (February, 2016), pp. 235-241, ISSN 0278-2715 [doi]  [abs]
  17. Regnier, SA; Ridley, DB, Market watch: Forecasting market share in the US pharmaceutical market., Nature reviews. Drug discovery, vol. 14 no. 9 (September, 2015), pp. 594-595, ISSN 1474-1776 [doi]
  18. Regnier, SA; Ridley, DB, Forecasting Market Share in the US Pharmaceutical Market, Nature Reviews Drug Discovery. 2015., vol. 14 no. 9 (July, 2015)
  19. Arcidiacono, P; Ellickson, PB; Landry, P; Ridley, DB, Pharmaceutical followers, International Journal of Industrial Organization, vol. 31 no. 5 (November, 2013), pp. 538-553, Elsevier BV, ISSN 0167-7187 [doi]  [abs]
  20. Arcidiacono, P; Ellickson, PB; Landry, P; Ridley, DB, Pharmaceutical Followers (October, 2013)
  21. Gans, JS; Ridley, DB, Innovation incentives under transferable fast-track regulatory review, Journal of Industrial Economics, vol. 61 no. 3 (September, 2013), pp. 789-816, WILEY, ISSN 0022-1821 [doi]  [abs]
  22. Ridley, DB, Payments, promotion, and the purple pill, Health Economics (United Kingdom), vol. 24 no. 1 (2013), pp. 86-103, ISSN 1057-9230 [doi]  [abs]
  23. Ridley, DB; Sánchez, AC, Introduction of European priority review vouchers to encourage development of new medicines for neglected diseases., Lancet, vol. 376 no. 9744 (September, 2010), pp. 922-927 [20833303], [doi]  [abs]
  24. Picone, GA; Ridley, DB; Zandbergen, PA, Distance decreases with differentiation: Strategic agglomeration by retailers, International Journal of Industrial Organization, vol. 27 no. 3 (May, 2009), pp. 463-473, Elsevier BV, ISSN 0167-7187 [doi]  [abs]
  25. Moe, J; Grabowski, H; Ridley, D, FDA review vouchers., The New England journal of medicine, vol. 360 no. 8 (February, 2009), pp. 837, ISSN 0028-4793 [doi]
  26. Ridley, DB, Herding versus Hotelling: Market entry with costly information, Journal of Economics and Management Strategy, vol. 17 no. 3 (September, 2008), pp. 607-631, WILEY, ISSN 1058-6407 [doi]  [abs]
  27. Ridley, DB, International price comparisons for novel and follow-on drugs., Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, vol. 10 no. 6 (November, 2007), pp. 510-511, ISSN 1098-3015 [doi]
  28. Kyle, MK; Ridley, DB, Would greater transparency and uniformity of health care prices benefit poor patients?, Health affairs (Project Hope), vol. 26 no. 5 (September, 2007), pp. 1384-1391, ISSN 0278-2715 [doi]  [abs]
  29. Grabowski, HG; Ridley, DB; Schulman, KA, Entry and competition in generic biologics, Managerial and Decision Economics, vol. 28 no. 4-5 (June, 2007), pp. 439-451, WILEY, ISSN 0143-6570 [repository], [doi]  [abs]
  30. Ridley, DB; Axelsen, KJ, Impact of Medicaid preferred drug lists on therapeutic adherence., PharmacoEconomics, vol. 24 Suppl 3 (January, 2006), pp. 65-78, ISSN 1170-7690 [17266389], [doi]  [abs]
  31. Ridley, DB; Kramer, JM, Postapproval drug safety: The authors respond [8], Health Affairs, vol. 25 no. 4 (January, 2006), pp. 1187-1188, Health Affairs (Project Hope), ISSN 0278-2715 [doi]
  32. Ridley, DB; Kramer, JM, Postapproval drug safety: The authors respond, HEALTH AFFAIRS, vol. 25 no. 4 (2006), pp. 1187-1188, Health Affairs (Project Hope), ISSN 0278-2715 [doi]
  33. Ridley, DB; Grabowski, HG; Moe, JL, Developing drugs for developing countries., Health Aff (Millwood), vol. 25 no. 2 (2006), pp. 313-324 [16522573], [doi]  [abs]
  34. Ridley, DB; Kramer, JM; Tilson, HH; Grabowski, HG; Schulman, KA, Spending on postapproval drug safety., Health Aff (Millwood), vol. 25 no. 2 (2006), pp. 429-436 [16522583], [doi]  [abs]
  35. Ridley, DB, Price differentiation and transparency in the global pharmaceutical marketplace., PharmacoEconomics, vol. 23 no. 7 (January, 2005), pp. 651-658, ISSN 1170-7690 [15987224], [doi]  [abs]
  36. Ridley, DB; Schulman, KA, Differential pricing of pharmaceuticals in the internet age., The Journal of ambulatory care management, vol. 27 no. 3 (July, 2004), pp. 210-214, ISSN 0148-9917 [15287210], [doi]  [abs]
  37. Shah, BR; Reed, SD; Francis, J; Ridley, DB; Schulman, KA, The cost of inefficiency in US hospitals, 1985-1997., J Health Care Finance, vol. 30 no. 1 (2003), pp. 1-9, ISSN 1078-6767 [12967239]  [abs]
Duke University * Arts & Sciences * Economics * Faculty * Research * Staff * Master's * Ph.D. * Reload * Login